$10,000 of ADIAL PHARMACEUTICALS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"FDA issues related to Addiction"
You can find more data on corporate lobbying on Quiver Quantitative.
ADIL Hedge Fund Activity
We have seen 8 institutional investors add shares of ADIL stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 143,791 shares (+inf%) to their portfolio in Q3 2025, for an estimated $50,830
- VANGUARD GROUP INC added 142,865 shares (+1085.7%) to their portfolio in Q3 2025, for an estimated $50,502
- GEODE CAPITAL MANAGEMENT, LLC added 95,277 shares (+138.4%) to their portfolio in Q3 2025, for an estimated $33,680
- TWO SIGMA SECURITIES, LLC added 12,841 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,539
- JANE STREET GROUP, LLC removed 12,521 shares (-50.4%) from their portfolio in Q3 2025, for an estimated $4,426
- TWO SIGMA INVESTMENTS, LP removed 10,802 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,818
- PRIVATE MANAGEMENT GROUP INC added 10,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,535
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ADIL Analyst Ratings
Wall Street analysts have issued reports on $ADIL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for ADIL, check out Quiver Quantitative's $ADIL forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
